Oxford Global Conferences are pleased to announce the 6th Annual Drug Development Congress, taking place at the Intercontinental Geneva on 2 & 3 June. It is estimated that less than 10% of drug development programmes result in safe and efficacious therapies. This congress brings together a host of drug development experts to discuss how we can strengthen the link between innovative science and clinical success. Day One of the congress covers key advances in predictive science, such as stem cell technologies for predictive modeling and novel biomarker technology for safety prediction. Speakers will discuss methods of achieving physiologically relevant models and compare strategies for tackling predictive challenges, such as complex biologics and multi-target drugs. Day Two of the congress looks at the way translational research can unlock the potential of early stage pipelines. Presentations will explore ways of harmonising ADMET strategy in discovery and development, integrating toxicology practices throughout the pipeline and improving the use of imaging in translational research. Delegates will also hear case studies concerning key tools for translational medicine, including novel immunoassays, resistance biomarkers and quantitative science applications.